久久综合日本久久综合,亚洲成AV人片在线观看天堂无码,国产在线视频不卡一区二区,久久久久看免费高清特色大片

武漢佰樂(lè)博生物技術(shù)有限公司
   
     
您當(dāng)前的位置: 網(wǎng)站首頁(yè) > 產(chǎn)品展廳 >試劑盒 >BioSim Pertuzumab ELISA Kit(KDC09602)
BioSim Pertuzumab ELISA Kit(KDC09602)
  • 品牌:AntibodySystem
  • 產(chǎn)地:France
  • 型號(hào):96 assays
  • 貨號(hào):KDC09602
  • 發(fā)布日期: 2022-07-25
  • 更新日期: 2024-10-23
產(chǎn)品詳請(qǐng)
產(chǎn)地 France
保存條件 2-8 ℃
品牌 AntibodySystem
貨號(hào) KDC09602
用途 For Research Use Only.
檢測(cè)方法 Elisa
CAS編號(hào)
保質(zhì)期 1 year
適應(yīng)物種 Pertuzumab
檢測(cè)限 0.156 ug /ml
數(shù)量 99999
包裝規(guī)格 96 assays
標(biāo)記物 Unconjugate
純度 95%%
樣本 Plasma, Serum
應(yīng)用 Elisa
是否進(jìn)口


Catalog No.

KDC09602

Stability and Storage

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.

Detection method

Colorimetric

Precision

CV<20%

Sample type

Plasma, Serum

Assay type

Quantitative

Sensitivity

0.156 μg/ml

Range

0.31-5 μg/mL

Recovery

80-120%

Specifications

Pertuzumab

Alternative Names

OMNITARG, rhuMAB 2C4, CAS: 380610-27-5

Background

Pertuzumab (also called 2C4, trade name Perjeta) is a humanized (from mouse) monoclonal antibody (mAb) used in combination with trastuzumab and docetaxel for the treatment of metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer; it also used in the same combination as a neoadjuvant in early HER2-positive breast cancer. It was discovered and developed by Genentech, a subsidiary of Roche, and was first approved in 2012. It is manufactured recombinantly in Chinese hamster ovary (CHO) cells. The monoclonal antibody 2C4 appears to have first been published in 1990 by scientists from Genentech. By 2003 Genentech understood that 2C4 prevented HER2 dimerizing with other HER receptors and had begun Phase I trials, aiming for a broad range of cancers, not just one’s overexpressing HER2. It was the first known HER dimerization inhibitor. In 2005 Genentech presented poor results of Phase II trials of pertuzumab as a single agent in prostate, breast, and ovarian cancers, and said that it intended to continue developing it in combination with other drugs for ovarian cancer. In 2007 Genentech dropped the trade name Omnitarg. In 2012 the results were published of the CLEOPATRA trial, a randomized placebo-controlled Phase III trial of pertuzumab in combination with trastuzumab and docetaxel in HER2-positive metastatic breast cancer. Pertuzumab received US Food and Drug Administration (FDA) approval for the treatment of HER2-positive metastatic breast cancer later that year. The FDA approved the neoadjuvant indication in 2013. Pertuzumab was approved in Europe in 2013.

Shipping

2-8 ℃

Note

For Research Use Only.


Aiming to develop the most reliable bioreagents, AntibodySystem SAS was founded in 2019 in France by a team of professionals from top industrial companies and research institutes. The collective scientific and technical experiences in our team have brought breaking throughs in multiple product developments, including recombinant antibodies, recombinant proteins, biosimilar, RUO ELISA kits and other related products. By working with talented researchers and technicians, AntibodySystem continues to upgrade product qualities and lower the overall cost, offering accountable and affordable solutions for biolabs all over the world. Since its establishment, AntibodySystem has built long term and stable collaborations with academia, pharmaceutical industry, biotech companies and research hospitals, supporting their R&D by AntibodySystem's bioreagents with excellent data accuracy and reproducibility.




AntibodySystem由具有30多年蛋白抗體開(kāi)發(fā)經(jīng)驗(yàn)的 創(chuàng)立于法國(guó),專(zhuān)注于生命科學(xué)和生物制藥領(lǐng)域研究,總部位于法國(guó)斯特拉斯堡市。AntibodySystem自主開(kāi)發(fā)了高效、高產(chǎn)的真核重組表達(dá)系統(tǒng),利用該系統(tǒng)生產(chǎn)了高質(zhì)量的重組蛋白、抗體產(chǎn)品。目前產(chǎn)品包括藥物靶點(diǎn)蛋白以及對(duì)照抗體藥物、Invivo功能性抗體、SAA系列流式抗體、PEG抗體、磷酸化抗體、抗小分子抗體、ADA抗體、PK&ADA ELISA試劑盒。


普健生物作為AntibodySystem在亞洲區(qū)授權(quán) ,致力于為廣大科研工作者提供 的產(chǎn)品服務(wù)。

如果您對(duì)我們的產(chǎn)品感興趣,請(qǐng)聯(lián)系027-65279366。

以上產(chǎn)品僅用于科研,產(chǎn)品信息以產(chǎn)品 為準(zhǔn)






聯(lián)系方式
手機(jī):18162686757
微信掃一掃
离岛区| 读书| 烟台市| 姚安县| 宝山区| 乌审旗| 额济纳旗| 南靖县| 黄浦区| 天等县| 葵青区| 盘锦市| 古田县| 梅河口市| 安塞县| 凤庆县| 行唐县| 瓮安县| 盐津县| 潜江市| 大城县| 玉树县| 泰宁县| 哈尔滨市| 株洲县| 靖边县| 繁峙县| 县级市| 桓仁| 保山市| 菏泽市| 潼南县| 武宣县| 老河口市| 新源县| 方城县| 赣榆县| 井陉县| 岐山县| 乳山市| 嘉祥县|